Striatal Dopamine D2 receptors |
↓ |
Dunn et al., 2012; Haltia et al., 2007; Johnson & Kenney et al., 2010; Lindgren et al., 2018; Stice et al., 2011; Tomasi & Volkow, 2013; Bello et al, 2002 (though see also South and Huang 2008) |
↓ |
Koob and Le Moal 2005
|
Striatal Dopamine release |
↓ |
Geiger et al., 2009; Rada et al., 2010
|
↓ |
Koob and Le Moal, 2005
|
Striatal DA transporters |
↓ |
Speed et al., 2011; Cone et al., 2013
|
↓ |
Kuhar and Pilotte, 1996
|
Central amygdala CRF-CRF1 activity *effects are different depending on if examined during withdrawal or after chronic exposure. Arrows in this row refer to following withdrawal and not ongoing chronic exposure. |
↑ |
Cottone et al., 2009a; Iemolo et al., 2012; Micioni Di Bonaventura et al., 2014; Micioni Di Bonaventura et al., 2017b
|
↑ |
Bruijnzeel et al., 2009; Bruijnzeel et al., 2010; Knapp et al., 2004; Overstreet et al., 2004; Sommer et al., 2008; Skelton et al., 2007; Stinus et al., 2005; Basso et al., 1999; Sarnyai et al., 1995; George et al., 2007; Chu et al., 2007; Funk et al., 2007; Gehlert et al., 2007; Gilpin et al., 2008; Richardson et al., 2008; Sabino et al., 2006; Valdez et al., 2002; Specio et al., 2008; Greenwell et al., 2009; Roberto et al., 2010; Zorrilla et al., 2001; Heinrichs et al., 1995; Maj et al., 2003; McNally and Akil, 2002; Weiss et al., 2001; Richter and Weiss, 1999; Rodriguez de Fonseca et al., 1997; Marcinkiewcz et al., 2009; Iemolo et al., 2013; Roberto et al., 2017
|
NAc preproenkephalin mRNA |
↓ |
Spangler et al., 2004; Kelley et al., 2003
|
↓ |
Spangler et al., 2004
|
Naloxone/naltrexone withdrawal |
↑ |
Colantuoni et al., 2002; Avena et al., 2008; Mason et al., 2015
|
↑ |
Pothos et al., 1991; Skelton et al., 2007; Zhang et al., 2016a
|
NAc Ach |
↑ |
Colantuoni et al., 2002; Avena et al., 2008; Hoebel et al., 2007
|
↑ |
Pothos et al., 1991; Rada et al., 1991; |